Developer docs
API playgroundTry for free, no card

Search company profiles

Comet Therapeutics

Full company profile

uuid0003cxi

Namestring
Comet Therapeutics
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Comet Therapeutics is a Cambridge, Massachusetts-based biotechnology company founded in 2018 that develops therapies intended to treat orphan neurological disorders. The company operated as a small, privately held, for-profit entity with 1-10 employees, and is led by CEO and President David de Graaf, founder and CTO Enej Kuscer, Chief Scientific Officer Arthur Taveres, and independent Chairman Peter Van Vlasselaer.

The company raised a single disclosed financing round: a $28.5 million Series 2 on June 19, 2019, co-led by Canaan Partners and Sofinnova Partners with participation from Mission BioCapital and Inkef. No follow-on financings, partnerships, in-licensing deals, or pipeline disclosures are documented in the available data, and no products, indications, modality (small molecule, biologic, gene therapy, etc.), or clinical-stage assets are described.

Material operational signals point to dormancy or wind-down: the company's website domain (comettherapeutics.com) is listed for sale on HugeDomains at $4,295, with no substantive company content at that address. No revenue, customers, commercial partnerships, regulatory filings, or current headcount detail is available. As a result, the verifiable footprint is limited to its 2019 capital event and founding leadership, and any investment-grade assessment should treat the entity as effectively inactive absent new primary disclosures.

Short descriptiontext

Comet Therapeutics is a Cambridge, MA-based biotech founded in 2018 that develops therapies for orphan neurological disorders. The company raised $28.5 million in a 2019 Series 2 led by Canaan Partners and Sofinnova Partners, and its operating domain is currently listed for sale.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
orphan neurological therapies, rare disease drug development, central nervous system therapeutics, biopharmaceutical research, neurological disorder treatments
Industry1 code
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Neurological Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Comet Therapeutics is a biotechnology company developing therapies intended to treat orphan neurological disorders. The company focuses on drug discovery and development for rare diseases of the central nervous system, targeting conditions with limited existing treatment options.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The source data is from a domain for sale listing page at HugeDomains.com for the domain name CometTherapeutics.com. This is not an active company website but rather a domain broker page indicating that the comettherapeutics.com domain is available for purchase at $4,295 (or $178.96/month for 24 months). No actual company information, products, or services for Comet Therapeutics were found in the available source data.

Product and service1 record
1Orphan neurological disorder therapies
CategoryBiopharmaceutical Therapies
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers7 records
TypeDirect peer
Description

Genetic medicines company focused on rare monogenic CNS disorders. Comparable therapeutic area (rare neuro) and platform-stage development profile.

TypeBroad incumbent
Description

Diversified rare-disease biotech with CNS programs in its portfolio. Comparable orphan-disease strategic orientation but operates as a multi-asset, publicly-listed holding company.

TypeBroad incumbent
Description

Established rare-disease leader with marketed neurological assets (e.g., enzyme replacement for CLN2). Comparable in orphan neuro positioning but at full commercial scale.

TypeDirect peer
Description

Late-stage rare disease biotech with neurological indications including Niemann-Pick disease type C. Comparable in orphan neuro focus and small-cap development model.

TypeBroad incumbent
Description

Commercial-stage rare-disease company with multiple neurological programs including for rare metabolic and CNS disorders. Comparable orphan-drug strategy and Cambridge-area presence.

TypeBroad incumbent
Description

Larger biotech developing therapeutics for neurodegenerative and rare neurological diseases. Comparable in CNS/rare neuro focus but operates at meaningfully greater scale and breadth.

TypeDirect peer
Description

Clinical-stage biotech developing therapies for rare neurological disorders, most notably X-linked adrenoleukodystrophy. Directly comparable to Comet in therapeutic area (orphan neuro) and stage profile.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Comet Therapeutics

Neurological Therapeuticscomettherapeutics.com

Comet Therapeutics is a Cambridge, MA-based biotech founded in 2018 that develops therapies for orphan neurological disorders. The company raised $28.5 million in a 2019 Series 2 led by Canaan Partners and Sofinnova Partners, and its operating domain is currently listed for sale.

What Comet Therapeutics does

Comet Therapeutics is a Cambridge, Massachusetts-based biotechnology company founded in 2018 that develops therapies intended to treat orphan neurological disorders. The company operated as a small, privately held, for-profit entity with 1-10 employees, and is led by CEO and President David de Graaf, founder and CTO Enej Kuscer, Chief Scientific Officer Arthur Taveres, and independent Chairman Peter Van Vlasselaer.

The company raised a single disclosed financing round: a $28.5 million Series 2 on June 19, 2019, co-led by Canaan Partners and Sofinnova Partners with participation from Mission BioCapital and Inkef. No follow-on financings, partnerships, in-licensing deals, or pipeline disclosures are documented in the available data, and no products, indications, modality (small molecule, biologic, gene therapy, etc.), or clinical-stage assets are described.

Material operational signals point to dormancy or wind-down: the company's website domain (comettherapeutics.com) is listed for sale on HugeDomains at $4,295, with no substantive company content at that address. No revenue, customers, commercial partnerships, regulatory filings, or current headcount detail is available. As a result, the verifiable footprint is limited to its 2019 capital event and founding leadership, and any investment-grade assessment should treat the entity as effectively inactive absent new primary disclosures.

Comet Therapeutics firmographics

Firmographics
Name
Comet Therapeutics
Website
https://comettherapeutics.com
Company type
Private
Founded year
2018
Headcount range
1–10 employees
Short description
Comet Therapeutics is a Cambridge, MA-based biotech founded in 2018 that develops therapies for orphan neurological disorders. The company raised $28.5 million in a 2019 Series 2 led by Canaan Partners and Sofinnova Partners, and its operating domain is currently listed for sale.
Ownership category
akta.pro rank

Comet Therapeutics industry classification

Industry
Product category
Neurological Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Orphan neurological therapies
  • Rare disease drug development
  • Central nervous system therapeutics
  • Biopharmaceutical research
  • Neurological disorder treatments

Where Comet Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Comet Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Comet Therapeutics product offering

Product offering

Core offering

Comet Therapeutics is a biotechnology company developing therapies intended to treat orphan neurological disorders. The company focuses on drug discovery and development for rare diseases of the central nervous system, targeting conditions with limited existing treatment options.

Product overview

The source data is from a domain for sale listing page at HugeDomains.com for the domain name CometTherapeutics.com. This is not an active company website but rather a domain broker page indicating that the comettherapeutics.com domain is available for purchase at $4,295 (or $178.96/month for 24 months). No actual company information, products, or services for Comet Therapeutics were found in the available source data.

Differentiator

Problem solved

Functional benefit

Products and services

  • Orphan neurological disorder therapies

Companies that use Comet Therapeutics

Customer profile

Ideal customer profiles1 record

Comet Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Comet Therapeutics partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights1 record

Comet Therapeutics competitors and assessment

Company assessment

Direct peers

  • Passage Bio: Genetic medicines company focused on rare monogenic CNS disorders. Comparable therapeutic area (rare neuro) and platform-stage development profile.
  • IntraBio: Late-stage rare disease biotech with neurological indications including Niemann-Pick disease type C. Comparable in orphan neuro focus and small-cap development model.
  • Minoryx Therapeutics: Clinical-stage biotech developing therapies for rare neurological disorders, most notably X-linked adrenoleukodystrophy. Directly comparable to Comet in therapeutic area (orphan neuro) and stage profile.

Broad incumbents

  • BridgeBio Pharma: Diversified rare-disease biotech with CNS programs in its portfolio. Comparable orphan-disease strategic orientation but operates as a multi-asset, publicly-listed holding company.
  • BioMarin Pharmaceutical: Established rare-disease leader with marketed neurological assets (e.g., enzyme replacement for CLN2). Comparable in orphan neuro positioning but at full commercial scale.
  • Ultragenyx Pharmaceutical: Commercial-stage rare-disease company with multiple neurological programs including for rare metabolic and CNS disorders. Comparable orphan-drug strategy and Cambridge-area presence.
  • Denali Therapeutics: Larger biotech developing therapeutics for neurodegenerative and rare neurological diseases. Comparable in CNS/rare neuro focus but operates at meaningfully greater scale and breadth.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Comet Therapeutics social profiles

Digital presence

Comet Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Comet Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Comet Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Comet Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Comet Therapeutics

What does Comet Therapeutics do?

Comet Therapeutics is a biotechnology company developing therapies intended to treat orphan neurological disorders. The company focuses on drug discovery and development for rare diseases of the central nervous system, targeting conditions with limited existing treatment options.

When was Comet Therapeutics founded?

Comet Therapeutics was founded in 2018. It employs 1 to 10 people.

Where is Comet Therapeutics based?

Comet Therapeutics is headquartered in Cambridge, United States, in the North America region.

Who are Comet Therapeutics's main competitors?

Direct peers on record are Passage Bio, IntraBio and Minoryx Therapeutics. Broad incumbents are BridgeBio Pharma, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical and Denali Therapeutics.

Does Comet Therapeutics have an API?

No public API is recorded for Comet Therapeutics.

What industry is Comet Therapeutics in?

Comet Therapeutics's product category is Neurological Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceVectivBio Announces Closing of Comet Therapeutics AcquisitionVectivBio Holding AG announced the closing of its acquisition of Comet Therapeutics, Inc., a privately held company developing drugs for Inherited Metabolic Diseases. The acquisition brings the CoMET platform, adding four drug programs targeting organic acidemias, urea cycle disorders, fatty acid oxidation disorders, and amino acidopathies, with the first candidate VB-1197 expected to enter Phase 1 trials within 18 months. The CoMET platform addresses IMDs that collectively affect over 75,000 people in the United States and Europe, including conditions with up to 40% mortality rates in patients by age 18.GlobeNewswireVectivBio to Acquire Comet Therapeutics and Host R&D DayVectivBio agreed to acquire Comet Therapeutics, a company developing a small-molecule platform for inherited metabolic diseases. The deal, valued at equity and cash with milestone payments, is expected to close by September 2021. VectivBio will host an R&D day on September 21, 2021, to present the platform.BioSpaceVectivBio to Acquire Comet Therapeutics and Host R&D DayVectivBio Holding AG announced a definitive agreement to acquire Comet Therapeutics, Inc., expanding its rare disease pipeline with the CoMET platform for treating Inherited Metabolic Diseases. The transaction involves equity and cash payments, including milestone-based considerations, and has been unanimously approved by both companies' boards of directors. VectivBio plans to close the acquisition by the end of September 2021 and will host an R&D Day to discuss the new platform alongside its existing programs.GlobeNewswireVectivBio to Acquire Comet Therapeutics and Host R&D DayVectivBio Holding AG announced a definitive agreement to acquire Comet Therapeutics, Inc., aiming to expand its rare disease pipeline with the CoMET small molecule platform. The transaction, approved by both boards, involves equity and cash payments and is expected to close by the end of September 2021. This acquisition adds four research programs targeting Inherited Metabolic Diseases to VectivBio's portfolio.VC News DailyComet Therapeutics Raises $28.5M Series AComet Therapeutics, a Cambridge, MA-based biotech company focused on Coenzyme A-related metabolism, has raised $28.5 million in Series A funding to develop a portfolio of drug candidates. The round was co-led by Canaan and Sofinnova Partners, with participation from INKEF Capital and BioInnovation Capital. The company plans to use the proceeds to expand its team and advance its CoMET Platform targeting metabolic, neuro-metabolic, and immuno-metabolic conditions.FinSMEsComet Therapeutics Raises $28.5M in Series A FinancingComet Therapeutics raised $28.5M in Series A funding co-led by Canaan and Sofinnova Partners. The company will use the funds to develop a portfolio of drug candidates targeting CoA-related metabolism, with potential applications in metabolic disorders and other conditions.